Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag Dose Escalation in MYH9-Related Disease
2008-001903-42Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in May-Hegglin anomaly (MHA) and Thrombocytopenia, sponsored by IRCCS San Matteo Foundation. Primary endpoint: Platelet count increase. Started Nov 2008; status: completed.
02
Drugs
eltrombopag
03
Conditions
May-Hegglin anomaly (MHA)Thrombocytopenia
Beyond the preview
Go deeper on 2008-001903-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001903-42.